Radiopharm Theranostics files KOL webinar 6-K

Radiopharm Theranostics Limited submitted a Form 6-K to provide U.S. investors with a copy of an announcement it lodged with the Australian Securities Exchange.

Rhea-AI Filing Summary

Radiopharm Theranostics Limited submitted a Form 6-K to provide U.S. investors with a copy of an announcement it lodged with the Australian Securities Exchange. The filing mainly furnishes an exhibit describing a key opinion leader webinar titled “Pivalate (Brain Mets) key opinion leader webinar.”

The document clarifies that this Form 6-K, including the attached exhibit, is furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if specifically referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Radiopharm Theranostics (RDPTF) disclose in this Form 6-K?

The Form 6-K furnishes an Australian Securities Exchange announcement. It attaches an exhibit describing a key opinion leader webinar titled “Pivalate (Brain Mets) key opinion leader webinar,” making the same information available to U.S. market participants.

What is Exhibit 99.1 in Radiopharm Theranostics (RDPTF) September 2025 Form 6-K?

Exhibit 99.1 is titled “Pivalate (Brain Mets) key opinion leader webinar.” It represents an announcement Radiopharm Theranostics released on the Australian Securities Exchange and is being furnished to U.S. investors through this Form 6-K.

Is Radiopharm Theranostics’ Form 6-K considered filed under the U.S. Exchange Act?

The Form 6-K explicitly states it is being furnished, not filed, under the U.S. Securities Exchange Act of 1934. It will only be incorporated into other U.S. securities filings if another document specifically references it.

Why did Radiopharm Theranostics (RDPTF) submit this Form 6-K to the SEC?

Radiopharm Theranostics submitted the Form 6-K to provide U.S. investors access to an Australian Securities Exchange announcement. The filing ensures the attached key opinion leader webinar information is also available in the U.S. disclosure system.

Who signed Radiopharm Theranostics’ September 2025 Form 6-K?

The Form 6-K was signed on behalf of Theranostics Limited by Phillip Hains, who is identified as the Company Secretary. The signature confirms the company has duly authorized submission of the furnished materials.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 08:26 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 15, 2025 titled:

-   “Pivalate (Brain Mets) key opinion leader webinar”  

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Pivalate (Brain Mets) key opinion leader webinar

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: September 15, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3